Addendum
Trifluridine/tipiracil (combination with bevacizumab; colorectal cancer) – Addendum to Project A23-85
Report documents
-
Addendum
Trifluridine/tipiracil (combination with bevacizumab; colorectal cancer) – Addendum to Project A23-85
Dossier assessment
Combination therapy with bevacizumab for the treatment of adults with metastatic colorectal cancer who have received 2 prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vascular endothelial growth factor agents, and/or anti-epidermal growth factor receptor agents
After addendum now: indication of major added benefit
Additional information
Federal Joint Committee (G-BA)
2024-02-15 A G-BA decision was published.
Project details
- Project no.
- A24-09
- Commission
- Commission awarded on 09.01.2024 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://dx.doi.org/10.60584/A24-09_en
Connected Projects
-
Dossier assessment
Trifluridine/tipiracil (combination with bevacizumab; colorectal cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed